



Published in final edited form as:

Cell Rep. 2022 August 02; 40(5): 111147. doi:10.1016/j.celrep.2022.111147.

## AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells

Natacha Comandante-Lou<sup>1,2,5</sup>, Douglas G. Baumann<sup>1,4,5</sup>, Mohammad Fallahi-Sichani<sup>1,3,6,\*</sup>

<sup>1</sup>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA

<sup>2</sup>Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA

<sup>3</sup>UVA Cancer Center, University of Virginia, Charlottesville, VA 22908, USA

<sup>4</sup>Present address: Dewpoint Therapeutics, 451 D Street, Suite 104, Boston, MA 02210, USA

<sup>5</sup>These authors contributed equally

<sup>6</sup>Lead contact

### SUMMARY

Cellular plasticity associated with fluctuations in transcriptional programs allows individual cells in a tumor to adopt heterogeneous differentiation states and switch phenotype during their adaptive responses to therapies. Despite increasing knowledge of such transcriptional programs, the molecular basis of cellular plasticity remains poorly understood. Here, we combine multiplexed transcriptional and protein measurements at population and single-cell levels with multivariate statistical modeling to show that the state of AP-1 transcription factor network plays a unifying role in explaining diverse patterns of plasticity in melanoma. We find that a regulated balance among AP-1 factors cJUN, JUND, FRA2, FRA1, and cFOS determines the intrinsic diversity of differentiation states and adaptive responses to MAPK inhibitors in melanoma cells. Perturbing this balance through genetic depletion of specific AP-1 proteins, or by MAPK inhibitors, shifts cellular heterogeneity in a predictable fashion. Thus, AP-1 may serve as a critical node for manipulating cellular plasticity with potential therapeutic implications.

### In brief

Comandante-Lou et al. show that a regulated balance between AP-1 protein levels and their transcriptional activities predict previously characterized heterogeneities in melanoma

\*Correspondence: fallahi@virginia.edu.

#### AUTHOR CONTRIBUTIONS

N.C.-L., D.G.B., and M.F.-S. conceived and designed the study and wrote the manuscript. N.C.-L. performed computational model analysis. D.G.B. developed protocols and performed the experiments. N.C.-L. and D.G.B. performed experimental data analysis. M.F.-S. supervised the work.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

#### INCLUSION AND DIVERSITY


We worked to ensure diversity in experimental samples through the selection of the cell lines. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community.

#### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2022.111147>.

differentiation states. Perturbing this balance, via genetic depletion of AP-1 proteins or pharmacological inhibition of the MAPK pathway, induces differentiation state switching and heterogeneity in a controllable manner.

## Graphical Abstract



## INTRODUCTION

Individual cells, even those derived from the same clone, respond heterogeneously to environmental perturbations (Mitchell and Hoffmann, 2018; Munsky et al., 2012). Nongenetic heterogeneity can arise because of variances associated with transcriptional state plasticity (Battich et al., 2015; Gupta et al., 2011; Munsky et al., 2012; Symmons and Raj, 2016). Although such plasticity is required for the proper development of complex organisms (Arias and Hayward, 2006), it limits the efficacy of therapies that target abnormally activated signaling pathways (Boumahdi and de Sauvage, 2020; Sharma et al., 2010). An example of cell-to-cell transcriptional heterogeneity with phenotypic consequences for therapy resistance is observed in melanomas (Emert et al., 2021; Fallahi-Sichani et al., 2017; Shaffer et al., 2017). Numerous studies have associated fluctuations in the state of MAPK inhibitor sensitivity across BRAF-mutant melanoma cells to intrinsic variations in their differentiation state (Baron et al., 2020; Belote et al., 2021; Khaliq et al., 2021; Rambow et al., 2018; Tsoi et al., 2018; Wouters et al., 2020). The reported heterogeneity spans a range of transcriptionally distinguishable states, including

a melanocytic phenotype that expresses melanocyte lineage markers SOX10 and MITF (Lin and Fisher, 2007), to less drug-sensitive states, including neural crest-like cells that express NGFR (Fallahi-Sichani et al., 2017; Mica et al., 2013) and innately drug-resistant, undifferentiated cells characterized by the overexpression of AXL and loss of SOX10 and MITF (Konieczkowski et al., 2014; Müller et al., 2014). In addition to intrinsic disparities in differentiation state, drug-induced responses may help a fraction of cells rewire their state of MAPK inhibitor sensitivity, most commonly through adaptive changes in differentiation state (Fallahi-Sichani et al., 2017; Marin-Bejar et al., 2021; Rambow et al., 2018; Smith et al., 2016) or via reactivation of the MAPK pathway (Gerosa et al., 2020; Lito et al., 2012). Although the emergence and consequences of such intrinsic and adaptive heterogeneities are widely recognized, there is still more to learn about their origins and possible connection at a molecular level. For example, it is unclear whether these seemingly distinct forms of heterogeneity arise from independent mechanisms or whether the observed variability in the initial state of cells and adaptive changes following MAPK inhibitor treatment could both be traced back to a common subset of molecular players.

Transcription factor networks that regulate the expression of genes in response to signaling pathway perturbations play a key role in creating the biological noise that leads to population heterogeneity (Huang, 2009; Pedraza and van Oudenaarden, 2005). The AP-1 protein family is one such network that serves as a major transcription node, integrating inputs from the upstream MAPK signaling pathway (Karin, 1995). In addition to linking signal transduction to transcription, AP-1 proteins have been recently identified to serve as pioneer factors, establishing chromatin states that predispose cells to transcriptional programs driven by other transcription factors or histone modifications, thereby guiding cells towards paths of differentiation or cell state reprogramming (Madrigal and Alasoo, 2018; Martínez-Zamudio et al., 2020; Phanstiel et al., 2017; Vierbuchen et al., 2017). These roles are consistent with numerous reports on AP-1 proteins' being involved in resistance to MAPK inhibitors, cell-state heterogeneity, and therapy-induced dedifferentiation in melanomas and other cancers (Emmons et al., 2019; Fallahi-Sichani et al., 2015, 2017; Haas et al., 2021; Johannessen et al., 2013; Kong et al., 2017; Maurus et al., 2017; Ramsdale et al., 2015; Riesenberg et al., 2015; Torre et al., 2021; Wouters et al., 2020). Despite these reports, we lack a clear understanding of the rules that define AP-1 behavior and its role in explaining the intrinsic plasticity and the diversity of adaptive responses to MAPK signaling perturbations. This gap in our knowledge may be addressed by a system-wide analysis with single-cell precision to reveal interdependencies between an array of AP-1 proteins, which constitute more than a dozen transcription factors, including JUN, FOS, and ATF subfamilies (Rodríguez-Martínez et al., 2017), their post-translational modification states, and their association with melanoma cell phenotypes at a single-cell level.

In this study, we test the hypothesis that the state of the AP-1 transcription factor network determines the intrinsic diversity of phenotypic states (i.e., differentiation states) and drug-induced changes in MAPK signaling in BRAF-mutated melanoma cells. We define the AP-1 state as the combinatorial concentrations of AP-1 proteins, their phosphorylation state, and their transcriptional activity, which are either measurable experimentally or inferable by using bioinformatics tools. Our systems biology approach combines multiplexed measurements of the AP-1 state, MAPK signaling activity, and differentiation state, at

population and single-cell levels, across many genetically characterized melanoma cell lines before and after their exposure to BRAF/MEK inhibitors. We apply statistical learning to capture the predictivity of AP-1 states, and corresponding AP-1 factors, for phenotypic heterogeneity in melanoma cultures and patient-derived tumors. We then use RNAi-mediated knockdown experiments to validate the causality of our statistical predictions in heterogeneous melanoma cell populations. We find that a tightly regulated balance between AP-1 transcription factors cJUN, JUND, FRA2, FRA1, and cFOS and their transcriptional activity determines the baseline differentiation state of melanoma cells. This balance is perturbed following MAPK pathway inhibition. Nevertheless, MAPK inhibitor-induced changes in the AP-1 state, including the abundance of cJUN and its phosphorylation, as well as the phosphorylation state of FRA1, remain strong predictors of drug-induced changes in differentiation state and the efficiency of MAPK pathway inhibition, respectively. These results show that the state of AP-1 network offers a critical transcriptional context, which controls not only the initial state of melanoma cells and their population heterogeneity but also their adaptive changes immediately following MAPK pathway inhibition.

## RESULTS

### Single-cell AP-1 protein levels predict differentiation state heterogeneity in melanoma cells

To quantify the baseline heterogeneities in differentiation state and to assess their covariation with AP-1 proteins across genetically diverse or isogenic melanoma cell populations, we used an iterative indirect immunofluorescence imaging (4i) protocol (Gut et al., 2018) in conjunction with high-throughput automated microscopy (Figure 1A). We multiplexed measurements of 21 proteins using 4i-validated antibodies in 19 BRAF-mutant melanoma cell lines (Figure 1B). The measurements included total levels of eleven AP-1 transcription factors (cFOS, FRA1, FRA2, cJUN, JUNB, JUND, ATF2, ATF3, ATF4, ATF5, and ATF6), six AP-1 phosphorylation states (p-cFOS<sup>S32</sup>, p-FRA1<sup>S265</sup>, p-cJUN<sup>S73</sup>, p-ATF1<sup>S63</sup>, pATF2<sup>T71</sup>, and p-ATF4<sup>S245</sup>), and four differentiation state markers (MITF, SOX10, NGFR, and AXL). Importantly, these four differentiation state markers were previously reported to represent transcriptionally distinct melanoma differentiation states (Khaliq et al., 2021; Tsoi et al., 2018). The panel of 19 melanoma cell lines tested represented a broad spectrum of differentiation states, including populations of melanocytic (MITF<sup>High</sup>/SOX10<sup>High</sup>/NGFR<sup>Low</sup>/AXL<sup>Low</sup>), transitory (MITF<sup>High</sup>/SOX10<sup>High</sup>/NGFR<sup>High</sup>/AXL<sup>Low</sup>), neuralcrest-like (MITF<sup>Low</sup>/SOX10<sup>High</sup>/NGFR<sup>High</sup>/AXL<sup>High</sup>), and undifferentiated (MITF<sup>Low</sup>/SOX10<sup>Low</sup>/NGFR<sup>Low</sup>/AXL<sup>High</sup>) cells (Figures 1C and S1A). We and others have shown that the frequency of these states in melanoma cell populations varies from one tumor to another and predicts their overall sensitivity to MAPK inhibitors (Khaliq et al., 2021; Rambow et al., 2018; Tirosh et al., 2016). Here, we asked whether the observed heterogeneities in differentiation state could be explained by variations in patterns of AP-1 measurements at a single-cell level.

The population-averaged and single-cell protein data revealed a high degree of variation in differentiation state markers and AP-1 proteins across genetically distinct cell lines (Figures 1B, 1C, and S1A). To test whether there is a relationship between AP-1 variations and the differentiation state of individual cells regardless of their genetic differences, we randomly

sampled a total of 10,000 cells, including 2,500 from each of the four differentiation states, in a way that they represented all 19 cell lines and 4 distinctive differentiation states as equally as possible (Figure 1D). We used the multiplexed AP-1 data of 80% of the cells to train a random forest classification model to predict the differentiation state of each individual cell. We then used the remaining 20% of the cell population to independently validate model predictions. Model-predicted single-cell differentiation states matched true (measured) differentiation states with accuracy of 0.74, representing a remarkable performance relative to a random 4-class classifier with an expected accuracy of 0.25 (Figure 1E). A close look at model predictions showed that they matched true states for 88% of undifferentiated cells, ~72% of neural crest-like cells, and ~66% of melanocytic cells. In cases in which the true and predicted state of a cell did not match, the model often predicted a closely related neighboring state along the differentiation state trajectory. When we combined cells from these related states (e.g., cells in melanocytic and transitory states), the model was able to distinguish them from the other two states in ~93% of the cases (Figure 1E).

To identify those AP-1 measurements that most strongly predicted single-cell differentiation state, we computed the shapley additive explanations (SHAP) values for the random forest classifications (Lundberg et al., 2020). SHAP assigns each AP-1 factor an importance value, quantifying its contribution, either positively or negatively, to the predicted differentiation state of any given cell (Figure 1F). Among the most important AP-1 factors (ranked on the basis of mean absolute SHAP values) were p-cFOS, FRA2, ATF4, cFOS, p-FRA1, and cJUN. Single-cell measurements of these six factors made it possible to predict the differentiation state of a cell with accuracy of 0.67 (Figure 1G).

We then asked whether models trained on the basis of the top six AP-1 factors would be able to predict the differentiation state of new cells from independent cell lines not included in model training. To answer this question, we iteratively removed one cell line, built a model using randomly sampled cells from the remaining 18 cell lines, and then used the trained model to predict the differentiation state of randomly selected cells from the left-out cell line. We observed that prediction accuracy for left-out cell lines was variable, with an average value of  $0.49 \pm 0.14$  across all 19 iterations (Figures S1B and S1C). We also noticed that although prediction accuracy for some left-out cell lines was greater than that of the full model (e.g., ~0.87 for LOXIMVI cells), predictions for two left-out cell lines (including IGR39 and SKMEL19) underperformed the random model. To test whether the lower performance of model predictions for a few cell lines could be attributed to any common patterns of misclassification, we examined the single-cell predictions for each left-out cell line separately (Figure S1D). We found that in most cases, misclassification occurred when the model failed to distinguish between closely related neighboring states (e.g., neural crest-like versus undifferentiated cells in IGR39 or transitory versus neural crest-like cells in SKMEL19). When we combined cells from such closely related states, the models were able to distinguish them from the other two states in >80% of the cases (Figure S1C).

Together, these analyses revealed that the heterogeneity in melanoma differentiation state was associated with distinguishable patterns of variation in the expression of a few key AP-1

proteins. In agreement with the SHAP analysis and model validation results, dimensionality reduction by uniform manifold approximation and projection (UMAP) (Becht et al., 2018) using only the top six AP-1 factors resulted in a cell trajectory ordered from melanocytic to undifferentiated states (Figures 1H and 1I). The UMAP projection also showed that melanocytic and transitory cells expressed substantially higher levels of p-cFOS, cFOS, and ATF4, whereas undifferentiated cells exhibited lower levels of all these factors and instead exhibited increased levels of FRA2, cJUN, and p-FRA1.

### AP-1 transcript levels predict variations in differentiation state programs across melanoma lines

To test whether the relationships between the patterns of AP-1 expression and melanoma differentiation state were recapitulated at the transcriptional level, we analyzed a previously published dataset, including RNA sequencing of 53 melanoma cell lines (Tsoi et al., 2018). Each cell line was assigned a series of seven signature scores, defined as the average of  $Z$  scores for the expression levels of differentiation state signature genes (Tsoi et al., 2018). The differentiation signature scores were then related to the transcript levels of 15 AP-1 genes for each cell line by partial least-squares regression (PLSR) (Figure 2A). The overall performance of the PLSR model was evaluated by computing the fraction of variance in signature scores explained ( $R^2$ ) or predicted ( $Q^2$ ) by changes in AP-1 gene expression (Figure 2B). The model revealed high performance and prediction accuracy with  $R^2$  of 0.72 and  $Q^2$  of 0.55 (using leave-one-out cross-validation) for four PLSR components. To evaluate the accuracy of predictions for each differentiation state, we assessed the correlation between the signature scores derived from the differentiation signature genes and scores predicted by the PLSR model. The model showed consistent accuracy, with an average Pearson's correlation coefficient of  $0.74 \pm 0.08$  ( $p = 3.2 \times 10^{-17}$  to  $1.3 \times 10^{-6}$ ) between the actual and predicted signature scores (Figure 2A). To independently validate the model predictions, we used RNA sequencing data from a different panel of 32 BRAF-mutant melanoma cell lines in the Cancer Cell Line Encyclopedia (CCLE) (Ghandi et al., 2019). The PLSR model trained against the original set of 53 cell lines was able to predict the differentiation signature scores in the new set of 32 melanoma cell lines, leading to an average Pearson's correlation coefficient of  $0.65 \pm 0.13$  ( $p = 2.3 \times 10^{-8}$  to  $6.8 \times 10^{-3}$ ) between the actual and predicted scores (Figure 2C).

The high performance of the PLSR model shows that variations in the transcriptional levels of at least some AP-1 genes may explain the variability in differentiation states across melanoma cell lines. In agreement with this expectation, different cell lines could be separated by their PLSR scores on the basis of their positions along the different state trajectory (Figure 2D). Because the PLSR model achieved its maximum prediction accuracy by four components, we computed the variable importance in projection (VIP) scores across all these components to determine the overall contribution of each AP-1 gene to each differentiation state (Figure 2E). Among the most important predictors of differentiation state (determined by  $|\text{VIP}| > 1$ ) were the expression of FOS (encoding cFOS), FOSL1 (encoding FRA1), FOSL2 (encoding FRA2), JUN (encoding cJUN), JUNB, JUND, ATF2, and ATF4 (Figure 2E). Importantly, a model created using only these AP-1 genes was able to significantly outperform most PLSR models that were built on the basis of combinations

of eight randomly chosen transcription factors from the basic leucine zipper (bZIP) family (the family to which AP-1 factors belong) ( $p = 0.008$ ) or on the basis of any eight randomly chosen transcription factors ( $p = 0.01$ ) (Figure 2F).

Together, these analyses revealed that the predictivity of patterns of AP-1 variation for melanoma differentiation state could also be captured at the level of transcription of these factors. Except for ATF4, the statistical association of AP-1 factors with differentiation state was generally consistent across bulk transcript and single-cell protein measurements (Figure S2A). Melanocytic and transitory cells expressed substantially higher levels of FOS transcript and cFOS protein levels, whereas undifferentiated cells were associated with increased levels of FOSL1, FOSL2, and JUN transcripts and their corresponding proteins FRA1, FRA2, and cJUN, respectively.

### **Single-cell network inference reveals the role of AP-1 activity in regulation of differentiation programs**

Next, we asked whether the statistical associations between the identified key AP-1 proteins and single-cell differentiation states resulted from the active regulation of differentiation programs by the AP-1 factors. To address this question, we applied single-cell regulatory network inference and clustering (SCENIC) (Aibar et al., 2017; Van de Sande et al., 2020) to analyze a previously published single-cell RNA sequencing dataset of 10 melanoma cell lines (Wouters et al., 2020). SCENIC uses single-cell gene expression data to infer transcription factors alongside their candidate target genes (collectively called a regulon), enabling the identification of regulatory interactions and transcription factor activities with high confidence. In line with our results from the gene and protein expression analyses, SCENIC analysis found the FOSL2 and JUN motif regulons to be substantially enriched in populations of undifferentiated cells in comparison with melanocytic, transitory, and neural crest-like cells (Figures 3A and 3B). The activity of the FOSL1 regulon was low in melanocytic cells but gradually increased among transitory, neural crest-like, and undifferentiated cells (Figure 3C). The FOS regulon, on the other hand, was substantially enriched in melanocytic and transitory cells, but its activity was low in undifferentiated and neural crest-like cells (Figure 3D).

To test whether the relationship between AP-1 regulon activities and melanoma differentiation states existed in single cells derived from tumor biopsies, we performed differentiation state enrichment and SCENIC analysis on single-cell RNA sequencing data previously collected via dissociation and profiling of patient-derived melanoma samples (Jerby-Aron et al., 2018; Tirosh et al., 2016). Accounting for missing values in a subset of differentiation signature genes, enrichment analysis of the 11 treatment-naive melanoma samples distinguished single cells from melanocytic and undifferentiated states with high confidence. SCENIC analysis of these cells showed that FOSL2, JUN, and FOSL1 regulons were significantly enriched in undifferentiated cells in comparison with melanocytic cells (Figures 3E–3G). In contrast to a substantially higher FOS regulon activity observed in cultured melanocytic cells, the activity of FOS regulon was only slightly higher in melanocytic tumor cells in comparison with undifferentiated cells (Figure 3H). Interestingly, however, the FOS/JUN activity ratio at a single-cell level was able to

distinguish melanocytic cells from undifferentiated cells more efficiently than either of these AP-1 factors alone (Figure 3I), suggesting that it is the balance between AP-1 factor activities that determines a cell's differentiation state.

Next, we asked how the key AP-1 transcription factor activities and their activity ratios varied between the widely recognized two-class “proliferative” and “invasive” phenotypes in melanoma cells (Hoek et al., 2006). Following single-cell enrichment analysis of the transcriptional signatures defined for these phenotypes (Hoek et al., 2006), we compared their associations with the activity of key AP-1 regulons inferred by SCENIC. As expected, the invasive phenotype exhibited higher activities of FOSL1, FOSL2, and JUN, whereas proliferative cells showed a higher FOS/JUN activity ratio (Figures S2B–S2K). Together, these analyses revealed that melanoma cells of diverse differentiation states are associated with distinct regulatory network activities by AP-1 transcription factors. In particular, the role of FOS, FOSL1, FOSL2, and JUN regulon activities was consistent with their corresponding patterns of gene and protein expression across melanoma differentiation states at both population and single-cell levels.

### **MAPK inhibitor-induced changes in the AP-1 state predict changes in differentiation state**

Although melanoma populations consist of stable mixtures of cells in diverse differentiation states at baseline, they can switch state in response to environmental perturbations. Specifically, treatment with MAPK inhibitors has been reported to induce changes in cell state that are associated with either activation of an MITF<sup>High</sup> program triggering melanocytic differentiation (Rambow et al., 2018; Smith et al., 2016) or downregulation of MITF activity and induction of an NGFR<sup>High</sup>, neural crest-like state (Fallahi-Sichani et al., 2017; Rambow et al., 2018). Such adaptive phenotype switching occurs with as little as 3 days of exposure to MAPK inhibitors and concomitantly with changes in MITF and NGFR protein expression (Khaliq et al., 2021). To determine common patterns of AP-1 changes that might be associated with drug-induced changes in differentiation state in either direction (i.e., differentiation or dedifferentiation), we exposed 18 BRAF-mutant melanoma cell lines to the BRAF inhibitor vemurafenib (at 0.316  $\mu$ M) either alone or in combination with the MEK inhibitor trametinib (at 0.0316  $\mu$ M). We fixed the cells following 24 or 72 h of treatment and then used the 4i procedure to measure the abundance or phosphorylation state of AP-1 transcription factors as well as MITF and NGFR protein levels (Figures 4A, S3, S4, and S5A). We also measured p-ERK<sup>T202/Y204</sup> levels to quantify changes in MAPK signaling as described in the following section (Figure S5B).

To assess drug-induced changes in differentiation state for each cell line, we computed the relative enrichment of dedifferentiated cells by normalizing the NGFR protein levels to MITF protein levels at baseline (DMSO), then tracking its changes following MAPK inhibitor treatments. Interestingly, treatment with BRAF/MEK inhibitors induced dedifferentiation in some cell lines (Figure 4B, left panels) but enhanced differentiation in a few others (Figure 4B, right panels). To identify possible associations between AP-1 factors and drug-induced changes in differentiation state, we built a PLSR model to associate DMSO-normalized changes in the expression levels of each of the AP-1 factors to DMSO-normalized changes in the enrichment of dedifferentiated (or abatement of differentiated)



cells for each of the MAPK inhibitor treatment conditions. The PLSR model achieved its maximum prediction accuracy by three components (Figure 5A). We thus computed the VIP scores using the first three PLS components to determine the overall contribution of each AP-1 modification to drug-induced changes in melanoma differentiation state (Figure 5B). VIP analysis revealed changes in multiple AP-1 factors from the JUN and ATF subfamily that were correlated with changes in differentiation state. Among these factors, cJUN and p-cJUN changes (at 24 and 72 h) were consistently the strongest predictors of both drug-induced dedifferentiation and differentiation among the tested cell lines (Figure 5C). In agreement with population-level data, single-cell analysis revealed increases in cJUN and p-cJUN levels in dedifferentiating melanoma cells (Figure 5D, top row) and reduction of cJUN and p-cJUN levels in differentiating melanoma cells following MAPK inhibitor treatments (Figure 5D, bottom row).

### **MAPK inhibitor-induced changes in the AP-1 state reveal efficiency of ERK pathway inhibition across melanoma cell lines**

In addition to drug-induced changes in differentiation state, incomplete inhibition of the ERK pathway (or its reactivation following a transient period of ERK inhibition) is known as a common mechanism of resistance to BRAF inhibitors (Lito et al., 2012). Importantly, when ERK activity rebounds as early as a few hours after drug treatment, a small residual ERK activity (at the cell population level) may be sufficient to help cells escape the effect of BRAF inhibition (Gerosa et al., 2020; Khaliq et al., 2021). The combination of BRAF inhibitors with MEK inhibitors has been proposed as a strategy to overcome the ERK pathway rebound following BRAF inhibition alone (Lito et al., 2012). In agreement with this idea, all 18 melanoma cell lines treated with the combination of vemurafenib and trametinib showed significantly lower levels of residual p-ERK at 24 h in comparison with their responses to vemurafenib treatment for the same duration (Figures 6A and 6B). Drug combination also significantly reduced p-ERK rebound in comparison with vemurafenib treatment at 72 h. However, the extent of this effect was variable among different cell lines (Figures 6A and 6B). We thus asked which, if any, of the AP-1 factors might capture the observed differences in the efficiency of ERK pathway inhibition among different cell lines.

To answer this question, we used partial correlation analysis to assess pairwise relationships between p-ERK and AP-1 levels across 18 cell lines treated with either vemurafenib (for either 24 or 72 h) or the combination of vemurafenib and trametinib (for 72 h), while correcting for baseline (drug-naive) variations in the AP-1 protein levels (Figure 6C). This analysis identified p-FRA1 as the most consistent predictor of the efficiency of ERK pathway inhibition among all cell lines (Figures 6C and 6D). In agreement with population-level correlation analysis, single-cell analysis also revealed a significant covariance between p-ERK and p-FRA1 levels (Figure 6E). Such strong connection between p-FRA1 and p-ERK in drug-treated cells is consistent with FRA1 serving as a tightly coupled sensor of ERK activity (Gillies et al., 2017). Interestingly, however, FRA1 or p-FRA1 levels did not correlate with hyperactivated p-ERK levels when we performed pairwise correlation analysis on drug-naive BRAF-mutant cells. Instead, we found drug-naive p-ERK levels to be positively correlated with cFOS, p-cFOS, and ATF4 and negatively correlated with FRA2 and cJUN (Figure S6). All these AP-1 factors were predictors of melanoma differentiation

state. These observations are consistent with previous reports linking up-regulation of MITF to elevated ERK activity in BRAF-mutant melanoma cells (Wellbrock et al., 2008). In addition, they suggest that changes in ERK signaling following pharmacological inhibition of the pathway may lead to rewiring of AP-1 signaling.

### **Perturbation of AP-1 state by siRNA confirms its role in driving differentiation state heterogeneity**

We hypothesized that if the AP-1 state drives melanoma differentiation programs, then inducing perturbations in the AP-1 state will shift differentiation states in predictable ways. To test this hypothesis, we perturbed AP-1 factors in COLO858 melanoma cells by using pools of previously validated small interfering RNAs (siRNAs) to knock down the expression of five AP-1 genes (FOS, FOSL1, FOSL2, JUN, and JUND), either individually or in pairwise combinations. Unfortunately, we were unable to achieve significant depletion of FRA1 in COLO858 cells. Hence, we focused on the analysis of the data following individual, or pairwise combinations of siRNAs targeting FOS, FOSL2, JUN, and JUND. COLO858 represents a heterogeneous population composed of both melanocytic (SOX10<sup>High</sup>/MITF<sup>High</sup>) and undifferentiated (SOX10<sup>Low</sup>/MITF<sup>Low</sup>) cells, thereby allowing us to track changes in the expression of differentiation state markers after AP-1 perturbations. Following 96 h of AP-1 gene knockdown in COLO858 cells, we measured (in three replicates) protein levels of differentiation markers MITF, SOX10, and AP-1 factors cFOS, FRA1, FRA2, cJUN, and JUND using 4i (Figures 7A, 7B, and S7).

Interestingly, siRNA-mediated knockdowns not only reduced the levels of AP-1 proteins targeted by their corresponding siRNAs but also, in some cases, led to changes in the expression of other AP-1 proteins (Figures 7A and S7). For example, FOSL2 knockdown substantially reduced FRA2 levels but also induced the expression of FRA1 compared with cells treated with non-targeting (control) siRNA. JUND knockdown reduced JUND levels but also led to an increase in cFOS and cJUN levels. These observations agree with previous findings (Lopez-Bergami et al., 2010) suggesting that the state of AP-1 network is controlled by interactions among different AP-1 factors. Combinations of siRNAs against pairs of AP-1 genes may help reveal AP-1 modifications that are phenotypically consequential. To identify such interactions, we quantified the levels of SOX10 and MITF proteins across all knockdown conditions in COLO858 cells and examined them along a two-dimensional plot (Figures 7A and 7B). We found that knocking down FOSL2 and JUN in combination significantly increased the expression of SOX10 (Figures 7A and 7B). This behavior is consistent with our earlier finding regarding the role of FRA2 and cJUN in regulation of the undifferentiated (SOX10<sup>Low</sup>) state. On the other hand, knocking down FOS and JUND in combination significantly reduced the expression of both MITF and SOX10 (Figures 7A and 7B), which is consistent with our finding regarding their role in driving the melanocytic lineage.

To further validate the impact of depletion of AP-1 proteins on the expression of melanoma differentiation state markers, we performed selected siRNA knockdown experiments in two additional cell lines, including C32 and LOXIMVI, which constituted relatively homogeneous populations of melanocytic and undifferentiated cells, respectively (Figure

1C). First, we exposed C32 cells to siRNAs targeting FOS and JUND, individually or in combination, for 96 h (Figure 7C). In agreement with results in COLO858 cells, the combination of FOS and JUND knockdown significantly reduced SOX10 and MITF protein levels in C32 cells (Figure 7C). Next, we exposed undifferentiated LOXIMVI cells to siRNAs targeting FOSL2 and JUN. We found that both siRNAs individually increased the expression levels of SOX10 (Figure 7). However, in contrast to our observation in COLO858 cells, the impact of combined FOSL2 and JUN siRNAs (for 96 h) in highly undifferentiated LOXIMVI cells was not significant. Overall, despite some differences among the impact of individual or combined siRNA treatments, the knockdown experiments across three cell lines (taken with all the data presented throughout this study) confirmed our findings regarding a key role for a balance among FOS, JUND, JUN, and FOSL2 in driving the differentiation program in melanoma cells.

## DISCUSSION

The hyperactivation of MAPK signaling in BRAF-mutant melanomas is linked to their overall sensitivity to MAPK inhibition. The differentiation state heterogeneity, however, leads to variability in MAPK inhibitor responses both across genetically diverse tumors and among genetically homogeneous populations of cells. Understanding the origins of such heterogeneity is key to identifying effective strategies to overcome fractional responses that undermine the potential of MAPK-targeted therapies. It requires a detailed knowledge of the mechanisms and molecular players that link cellular plasticity and transcriptional regulation of differentiation state to therapy-induced changes in MAPK signaling. To begin to fill this gap in our knowledge, we used a multidimensional approach at single-cell resolution to systematically investigate the AP-1 transcription factor contributions to heterogeneity in BRAF-mutant melanoma cells. We focus on the AP-1 factors because they serve as downstream targets of MAP kinases, and previous work has connected several AP-1 proteins to MAPK inhibitor resistance, differentiation state heterogeneity, and therapy-induced changes in differentiation state in melanomas.

Our data showed that a tightly regulated balance among a few key AP-1 family members and their activities strongly predict previously characterized heterogeneities in melanoma differentiation states. Specifically, cFOS and p-cFOS were associated with melanocytic and transitory cells, whereas FRA1, p-FRA1, FRA2, and cJUN and p-cJUN correlated with less differentiated cell states. The systematic nature of the study across many genetically different melanomas suggests that these associations are a general feature of melanomas and likely not unique to a particular cell line or linked to a certain genetic context. Furthermore, we showed that perturbing the molecular balance of AP-1 factors in melanoma cells by siRNAs that deplete specific AP-1 proteins, either alone or in combination, or by treatments with MAPK inhibitors can induce differentiation state switching and heterogeneity in a controllable manner. Together, these findings provide insights into AP-1 function, its role in cell state plasticity, and its potential dysregulation in melanoma, while opening avenues for interrogating the AP-1 behavior in the context of adaptive response to MAPK inhibitors. In theory, gaining the ability to target certain AP-1 states could force cells to remain in a more drug-sensitive state, thereby increasing the fractional killing of melanoma cells in response to MAPK inhibition.

Future studies may leverage the findings from this study to further elucidate transcriptional mechanisms that contribute to MAPK-targeted therapy escape in melanomas at a single-cell level. Furthermore, uncovering how the information encoded in the MAPK signaling dynamics is transduced through its downstream AP-1 network will be key for explaining the observed variability in tumor cell responses to MAPK inhibitors. For example, AP-1 family members FOS and FOSL1 are early ERK target genes whose regulation by ERK activity constitutes feedforward motifs that enable them to decode the dynamics of ERK signaling (Davies et al., 2020). Differentiation state-specific variations in the baseline expression and activities of these AP-1 genes, as we observed in this study, could introduce variability in the transduction of MAPK signals, generating heterogeneity in cell fate under MAPK perturbations. Future studies that link dynamic fluctuations in ERK activity and other MAP kinases to AP-1 behavior could offer important insights into mechanisms of heterogeneity in drug response and adaptive resistance to MAPK inhibitors.

Consistent with our findings regarding the role of AP-1 state changes in determining the differentiation state plasticity, recent studies have highlighted a key role for AP-1 factors in chromatin organization and enhancer accessibility. AP-1 proteins have been reported to facilitate new cell fate transitions, such as cellular senescence or differentiation, by establishing the enhancer landscape and granting long-term chromatin access to other transcription factors, thereby allowing the timely execution of cell state-specific transcriptional programs (Madrigal and Alasoo, 2018; Martínez-Zamudio et al., 2020; Phanstiel et al., 2017; Vierbuchen et al., 2017). Understanding which AP-1 factors and cofactors work to keep poised enhancers accessible and which function to shift enhancers from a poised to active state could connect transcription to (de)differentiation and genome reorganization following inhibition of MAPK signaling and its adaptive reactivation. Furthermore, AP-1 proteins like other bZIP proteins must form dimers before they could bind to the AP-1 motif site. For example, while FOS family members bind DNA as obligate heterodimers with members of the JUN family, JUN family members can bind the AP-1 motif site as both homodimers and heterodimers with FOS family members. Future studies, therefore, should also determine the extent to which the combinatorial activity of AP-1 family members is influenced by distinct patterns of dimerization among these transcription factors.

### Limitations of the study

Although quantitative, immunofluorescence-based measurements of protein levels and phenotypes and the use of siRNAs to knock down the expression of genes have proved immensely powerful for the study of biology, all techniques have limitations. For example, the quality of quantitative information retrieved from immunofluorescence images depends largely on the quality of segmentation of the cell features of interest. Although great effort was made to optimize the image segmentation procedure and to ensure that the segmentation captured the desired features, it is infeasible to visually inspect every cell for appropriate segmentation. Second, in the current study we assume that AP-1 protein levels in the nucleus correspond to or correlate with transcriptional activity. Although this assumption is likely true in many circumstances, it is impossible to definitively prove that this is the case for each of the many factors we measure in this study. Furthermore, when performing many

sequential rounds of 4i staining and images, cells are gradually lost over the course of sample washing and re-probing. Although we assume that cell loss occurs equivalently for all differentiation states of the cell, we do not explicitly test this assumption here. However, if this assumption were false, it would be unclear whether the conclusions reached in the paper would change, as our findings are validated using a variety of complementary methods and independent datasets.

## STAR★METHODS

### RESOURCE AVAILABILITY

**Lead contact**—Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Mohammad Fallahi-Sichani (fallahi@virginia.edu).

**Materials availability**—This study did not generate new unique reagents.

#### Data and code availability

- Raw immunofluorescence microscopy data reported in this paper will be shared by the lead contact upon request. All quantified microscopy data are included in Data S1, S4, S5, S6. This paper analyzes existing, publicly available data. These accession numbers for the datasets are listed in the key resources table.
- The original codes for data analysis performed in this paper are publicly available at GitHub: <https://github.com/fallahi-sichani-lab/AP1-networkPlasticityMelanoma> (<https://doi.org/10.5281/zenodo.6741989>).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

BRAF-mutant melanoma cell lines used in this study include: COLO858, RVH421, A375, A375(NRAS<sup>Q61K</sup>), C32, A2058, WM115, SKMEL28, HS294T, WM1552C, SKMEL5, A101D, IGR39, LOXIMV1, MMACSF, WM902B, WM2664, UACC62 and SKMEL19. All cell lines have been subjected to re-confirmation by short tandem repeat (STR) profiling by ATCC and mycoplasma testing by MycoAlert™ PLUS Mycoplasma Detection Kit. A375, A375(NRAS<sup>Q61K</sup>), A2058, HS294T, A101D, and IGR39 cells were grown in DMEM with 4.5 g/L glucose supplemented with 5% fetal bovine serum (FBS). SKMEL5 and WM2664 cells were grown in EMEM supplemented with 5% FBS. C32, MMACSF, SKMEL28, and WM115 cells were grown in DMEM/F12 supplemented with 1% sodium pyruvate and 5% FBS. COLO858, LOXIMVI, RVH421, SKMEL19, UACC62, WM1552C, and WM902B cells were grown in RPMI 1640 supplemented with 1% sodium pyruvate and 5% FBS. Cells were grown at 37°C with 5% CO<sub>2</sub> in a humidified chamber. 100 U/mL Penicillin-Streptomycin (10,000 U/mL), and 0.5 mg/mL Plasmocin Prophylactic were present in all cell cultures.

## METHOD DETAILS

**Drug treatments**—Cells were seeded in 200  $\mu\text{L}$ /well in Corning 96-well plates. Vemurafenib, Trametinib or vehicle (DMSO) was added at indicated concentrations using the Tecan D300e Digital Dispenser 24 h after cell seeding. Cells were fixed at the indicated timepoints with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at room temperature. All time course experiments with drug treatment were initiated at the same time and then stopped sequentially at the indicated timepoints (24 h and 72 h). The DMSO experiments were stopped at 24 h to avoid artifacts in signaling measurements that may arise due to cell confluency and the exhaustion of growth media.

**AP-1 gene knockdown by siRNA**—COLO858 cells were seeded in 100  $\mu\text{L}$  of antibiotic-free growth media (RPMI supplemented with 5% FBS and 1 mM Sodium Pyruvate) in 96-well plates at a density of 2000 cells/well. After 24 h of incubation, cells were transfected using 0.05  $\mu\text{L}$  of DharmaFECT 2 reagent per well with indicated Dharmacon ON-TARGETplus AP-1 siRNAs (at 25 nM) individually or in pairwise combinations. Knock-downs targeting a single AP-1 gene were supplemented with non-targeting siRNA to normalize the final siRNA concentration (to 50 nM siRNA) across all siRNA conditions. All siRNAs were tested for knockdown efficiency and specificity by measuring protein levels of each factor and members of the factor subfamily (e.g., measuring single-cell protein levels of cFOS, FRA1, and FRA2, 24 h following FOS knockdown). Only siRNA species that showed knockdown of the protein target with minimal off-target knockdown effects were used. Cells were fixed 96 h after transfection with 4% paraformaldehyde in PBS for 30 min at room temperature. The siRNA sequences used for each condition are included in Table S1.

**Iterative indirect immunofluorescence imaging (4i)**—4i images were obtained using a previously described protocol (Gut et al., 2018) with minor modifications. After media aspiration, cells in 96-well plates were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature. All washes were performed using a BioTek EL406 Washer Dispenser and consisted of 4 wash cycles of 200  $\mu\text{L}$  with the indicated buffer while retaining approximately 20  $\mu\text{L}$  liquid in each well during the aspiration step to limit cell loss. Cells were washed with PBS then permeabilized for 15 min at room temperature with 100  $\mu\text{L}$  0.5% Triton X-100 in PBS. Cells were washed with PBS followed by Milli-Q deionized water. Cells were next treated 3 times total for 12 min each instance with 40  $\mu\text{L}$  elution buffer which consists of 0.5M L-Glycine, 3M Urea, 3 M Guanidinium chloride, and 70 mM TCEP-HCl at pH of 2.5. Cells were washed with PBS as above. Samples were then blocked for 1 h at room temperature with 50  $\mu\text{L}$  blocking buffer which consists of PBS-based Intercept buffer supplemented with 150 mM maleimide. Blocking buffer was prepared immediately prior to adding to the samples for each round. Following a PBS wash, samples were incubated overnight at 4°C with 40  $\mu\text{L}$  primary antibody diluted in Intercept buffer. After overnight incubation, cells were washed with PBS then incubated for 1 h at room temperature in 40  $\mu\text{L}$  secondary antibody solution consisting of the appropriate species-specific Alexa Fluor-conjugated antibodies diluted 1:2000 in Intercept buffer. Cells were then washed with PBS and incubated with 50  $\mu\text{L}$  Hoechst 33342 diluted 1:20,000 in PBS. For the first round of imaging, cells were stained with a mixture of Hoechst and CellMask

Green for 30 min at room temperature according to the manufacturer's instructions. Next, cells were washed with Milli-Q water and 80  $\mu$ L imaging buffer consisting of 700 mM N-Acetyl-Cysteine at pH of 7.4. Images were obtained using Operetta CLS high content imaging system (Perkin Elmer) using a 10 $\times$  air objective lens. Following imaging, samples were washed with Milli-Q water after which antibodies were eluted with 3 successive 12-min incubations at room temperature with elution buffer. Cells were washed with PBS followed by Milli-Q water. Next, 50  $\mu$ L imaging buffer was added to each well and samples were imaged as above to assess removal of fluorescent signal. Cells were then washed with PBS and all steps were repeated starting at the blocking step for each round of 4i. In instances where the time between 4i rounds exceeded 3 days, following elution, the plates were fixed for 10 min at room temperature with 4% paraformaldehyde in PBS. In these cases, to resume staining, cells were then washed with PBS followed by Milli-Q water and treated with elution buffer lacking TCEP-HCl three times for 10 min, totaling 30 min. Afterwards, cells were washed with PBS and the next round of 4i commenced.

**Image analysis**—Images were background subtracted using the rolling ball subtraction algorithm in ImageJ (2.3.0). Background-subtracted images from each round of 4i were aligned using Hoechst nuclei staining with CellProfiler (3.1.9) (McQuin et al., 2018) using the normalized cross correlation method within the Align module. Nuclei were segmented from the aligned images using the Minimum Cross Entropy thresholding method within the IdentifyPrimaryObjects module in CellProfiler. The Threshold smoothing scale and correction factor were 2.4 and 1, respectively with lower and upper threshold bounds of 0 and 1. Cell segmentation was then performed using CellMask Green staining to propagate objects from the nuclei. This was done using the Propagation method within the IdentifySecondaryObjects module. The Minimum cross entropy thresholding method was used with a smoothing scale of 0 and correction factor of 1, the lower and upper threshold bound values set to 0 and 1, and a regularization factor of 0.05. The TrackObjects module was used to multiplex data from individual rounds of 4i. Within TrackObjects, the Follow Neighbors method was used with the maximum pixel distance of 50 and average cell diameter of 15. Comma-separated text files containing quantitative single-cell measurements of tracked objects from CellProfiler were organized using Matlab. Only objects present in every round of imaging were included in the analysis. Additional data analysis was performed using Matlab, R, and Python.

**Classifying melanoma differentiation states**—To classify the differentiation state of cells based on image-based protein measurements, we generated histograms of single-cell data on each of the previously validated melanoma differentiation state markers (MITF, SOX10, NGFR and AXL) (Khaliq et al., 2021; Tsoi et al., 2018). For each protein (X), we identified an appropriate binary gate, based on which individual melanoma cells were divided into two groups of X<sup>High</sup> and X<sup>Low</sup> cells. The gating thresholds used on background-subtracted image data for each protein included:  $\log(\text{MITF}) = 7.37$ ,  $\log(\text{SOX10}) = 6.82$ ,  $\log(\text{NGFR}) = 4.61$ , and  $\log(\text{AXL}) = 5.60$ . We then used these classifications to determine the differentiation subtype of each individual melanoma cell as follows: melanocytic (M): MITF<sup>High</sup>/SOX10<sup>High</sup>/NGFR<sup>Low</sup>/AXL<sup>Low</sup>; transitory (T): MITF<sup>High</sup>/SOX10<sup>High</sup>/NGFR<sup>High</sup>/AXL<sup>Low</sup>; neural crest-like (N): MITF<sup>Low</sup>/SOX10<sup>High</sup>/

Author Manuscript

NGFR<sup>High</sup>/AXL<sup>High</sup>; and undifferentiated (U): MITF<sup>Low</sup>/SOX10<sup>Low</sup>/NGFR<sup>Low</sup>/AXL<sup>High</sup>; the single-cell analysis and baseline differentiation state classification were performed across 19 different melanoma cell lines representing a wide spectrum of differentiation states. To classify the differentiation state of cells in gene knockdown perturbation assays, we used a similar approach to distinguish melanocytic/transitory (MITF<sup>High</sup>/SOX10<sup>High</sup>) cells from undifferentiated (MITF<sup>Low</sup>/SOX10<sup>Low</sup>) cells.

Author Manuscript

To classify melanoma differentiation states using bulk transcriptomic data, each melanoma cell line was assigned a series of seven differentiation signature scores, defined as the average of z-scores for the expression levels of differentiation state signature genes identified previously by Tsoi et al. (Tsoi et al., 2018). These differentiation signatures included the four main differentiation signatures, i.e., melanocytic (M), transitory (T), neural crest-like (N) and undifferentiated (U), as well as mixtures of neighboring signatures, including melanocytic-transitory (MT), transitory-neural crest-like (TN) and neural crest-like-undifferentiated states (NU).

Author Manuscript

To determine the differentiation state of individual cells for each of the 10 melanoma cell lines profiled by single-cell RNA sequencing (Wouters et al., 2020), we used the R package AUCell (1.16.0) to quantify the enrichment of differentiation signature genes (as defined by Tsoi et al. (Tsoi et al., 2018)) in individual cells. To minimize the impact of noise from single-cell data, we combined two or three closely related signature gene sets as follows: M-MT gene set (combination of M and MT signature genes), MT-T-TN gene set (combination of MT, T and TN signature genes), TN-N-NU gene set (combination of TN, N and NU signature genes) and NU-U set (combination of NU and U genes). We then selected cells that represented individual differentiation states based on their gated AUCell scores as follows: melanocytic cells: M-MT<sup>High</sup>/TN-N-NU<sup>Low</sup>/NU-U<sup>Low</sup>; transitory cells: M-MT<sup>Low</sup>/MT-T-TN<sup>High</sup>/TN-N-NU<sup>Low</sup>/NU-U<sup>Low</sup>; neural crest-like cells: M-MT<sup>Low</sup>/MT-T-TN<sup>Low</sup>/TN-N-NU<sup>High</sup>/NU-U<sup>Low</sup>; undifferentiated cells: M-MT<sup>Low</sup>/MT-T-TN<sup>Low</sup>/NU-U<sup>High</sup>. The differentiation state of individual melanoma cells derived from treatment-naïve patient tumors profiled by Tirosh et al. (Tirosh et al., 2016) and Jerby-Arnon et al. (Jerby-Arnon et al., 2018) were determined in the same way, except that only melanocytic and undifferentiated cells were identified and analyzed. To determine the two-class “proliferative” and “invasive” phenotypes of individual cells from the 10 cell lines and patient tumors, we used AUCell to quantify the enrichment of the two gene sets defined by Hoek et al. (Hoek et al., 2006) for these two phenotypes at the single-cell level. We then selected cells that represent each phenotype based on their gated AUCell, including proliferative cells as proliferative<sup>High</sup>/invasive<sup>Low</sup> and invasive cells as proliferative<sup>Low</sup>/invasive<sup>High</sup>.

Author Manuscript

**Random forest classification**—We used random forest classification to test the predictivity of AP-1 variations for melanoma differentiation state using single-cell protein data collected by immunofluorescence imaging of 19 melanoma cell lines. We randomly sampled a total of 10,000 cells, including 2,500 from each of the four differentiation states, in a way that they represented all 19 cell lines and 4 distinctive differentiation states (melanocytic, transitory, neural crest-like and undifferentiated) as equally as possible. By random sampling, we aimed to minimize potential biases associated with genotype



differences among cell lines. We used the data from 80% of the sampled cells to train a random forest classification model to predict the differentiation state of each individual cell. We then used the remaining 20% of cells to independently validate model predictions. We also evaluated the performance of random forest models in predicting differentiation states of independent cell lines using “leave-one-line-out” cross-validation. For this purpose, at each iteration, we excluded cells from one cell line, trained a model using the remaining 18 cell lines, and then used the trained model to predict the differentiation state of cells from the left-out cell line.

Model training, cross-validation and independent validation were all performed in Python (3.9.2) using the scikit-learn library (0.24.1) (Pedregosa et al., 2018). To standardize the model input, protein levels of each AP-1 measurement were normalized across cells to zero mean and unit variance (z-score scaled) using the StandardScaler() function. The random forest model was trained using the RandomForestClassifier() function. In training the full model with all 17 AP-1 factors, all parameters were as defined in the default settings, except the number of trees in the forest ( $n\_estimators = 100$ ) and maximum tree depth ( $max\_depth = 14$ ), which were separately optimized through 5-fold Stratified Shuffle Split cross-validation on the training set, using the StratifiedShuffleSplit() function with 10 times splitting iterations ( $n\_splits = 10$ ). In leave-one-line-out cross-validation, models built based on the top six AP-1 factors were trained using  $n\_estimators = 500$ , while other parameters were the same as in the full model.

The random forest model performance was evaluated based on accuracy and Area Under the Receiver Operating Characteristic Curve (ROC AUC). Accuracy reports the fraction of correctly classified samples, i.e., true positives and true negatives, and it was calculated using the accuracy\_score() function. The ROC AUC scores were calculated using the roc\_auc\_score() function with the One-vs-rest option ( $multi\_class = 'ovr'$ ), which computes the AUC of each class against the rest. The ROC AUC scores consider both the sensitivity (true positive rate) and specificity (true negative rate) of the model predictions.

To assess the importance of each AP-1 factor in explaining the predictions made by the random forest model for each individual cell in the independent validation set, we used the SHapley Additive exPlanations (SHAP) package (Lundberg and Lee, 2017). SHAP provides a model agnostic measure of feature importance based on Shapley values, which assign importance of input features based on their contribution to the model output prediction. Mathematically, given a specific prediction output by model  $f$  with input  $x$ , Shapley value for feature  $i$ ,  $\phi_i(f, x)$ , is the average of feature  $i$ 's marginal contributions across all possible orders of features being included (Lundberg and Lee, 2017; Lundberg et al., 2018):

$$\phi_i(f, x) = \sum_{S \subseteq \mathcal{S}_{all} \wedge \{i\}} \frac{|S|!(M - |S| - 1)!}{M!} [f_x(S \cup \{i\}) - f_x(S)]$$

where  $M$  is the total number of features,  $|S|$  denotes number of entries in set  $S$  and the Uterm  $f_x(S \cup \{i\}) - f_x(S)$  is the marginal contribution of feature  $i$ . In SHAP, the marginal impact of a feature is defined as the change in the expected value of the model output  $f(x)$  when that feature is observed versus unknown:

$$f_x(S \cup \{i\}) - f_x(S) = E[f(x) | x_S \cup \{i\}] - E[f(x) | x_S],$$

where  $x_S$  is a subset of features with only set  $S$  is observed.

**Partial least squares regression (PLSR) modeling**—We used PLSR analysis to test whether the relationships between the patterns of AP-1 gene expression and melanoma differentiation state were recapitulated at the transcriptional level. Bulk RNA sequencing data of 53 melanoma cell lines used for PLSR analysis were obtained from Tsoi et al. (Tsoi et al., 2018). We first  $\log_2$ -transformed the gene expression data (reported as FPKM) with an offset of 1. Input vectors for PLSR analysis were then created by combining the z-scored expression data for fifteen AP-1 transcription factor family genes, including FOS, FOSL1, FOSL2, FOSB, JUN, JUNB, JUND, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF6B and ATF7, across 53 cell lines. The response variables for each cell line were then assembled as a series of seven signature scores, defined as the average of z-scores for the expression levels of differentiation state signature genes (Tsoi et al., 2018). The PLSR model was trained in python using the scikit-learn library and the `PLSRRegression()` function. To evaluate the predictability of the linear relationship between the input and output variables using the same dataset, we used leave-one-out cross-validation by `LeaveOneOut()` function. To independently validate the model, we used RNA sequencing data from an independent panel of 32 melanoma cell lines in the Cancer Cell Line Encyclopedia (CCLE) (Ghandi et al., 2019). As with the training dataset, we first  $\log_2$ -transformed the CCLE gene expression data (reported as RPKM) with an offset of 1. We then created input vectors by combining the z-scored expression data for fifteen AP-1 transcription factor family genes and used them in the optimized PLSR model (using the first four PLS components) trained against the original set of 53 cell lines to predict the differentiation signature scores in the new set of 32 cell lines.

The PLSR model performance was evaluated in terms of fraction of variance explained ( $R^2$ ) or predicted ( $Q^2$ ) using the `explained_variance_score()` function. We assessed the relative importance of each AP-1 factor in the PLSR model based on the variable importance in projection (VIP) scores, computed for the first four PLS components, at which the PLSR model achieves its optimal performance (Wold, 1994). To help interpret the directionality of the contribution, we multiplied the VIP score for each AP-1 factor by the sign of Pearson correlation coefficient between its expression levels and differentiation signature z-scores.

We compared the performance (based on 10-fold cross validation) of optimized PLSR model, built based on the top eight AP-1 genes (FOS, FOSL1, FOSL2, JUN, JUNB, JUND, ATF2 and ATF4) with optimized models built using combinations of eight randomly chosen basic leucine zipper (bZIP) transcription factors (Vinson et al., 2002) or eight randomly chosen transcription factors (Van de Sande et al., 2020) (excluding those that were explicitly involved in the differentiation signature genes) by computing empirical p values using 100,000 and 500,000 iterations, respectively.

To identify dynamic patterns of AP-1 changes that are associated with drug-induced changes in differentiation state, we constructed a PLSR model to relate DMSO-normalized changes

in AP-1 proteins to DMSO-normalized changes in differentiation state. The input vector consists of DMSO-normalized population measurements of the seventeen AP-1 proteins, including cFOS, p-cFOS, FRA1, p-FRA1, FRA2, cJUN, p-cJUN, JUNB, JUND, p-ATF1, ATF2, p-ATF2, ATF3, ATF4, p-ATF4, ATF5 and ATF6, at 24 h and 72 h, z-scored across two MAPK inhibitor treatment conditions and eighteen cell lines. DMSO-normalized AP-1 measurements were calculated as the log ratios of drug-treated AP-1 levels relative to the DMSO control. The response vector is composed of the DMSO-normalized changes in differentiation state, which is calculated as  $\log\left(\frac{(NGFR/MITF)_{Drug}}{(NGFR/MITF)_{DMSO}}\right)$ . Model training, cross-validation and performance evaluation were performed the same way as in the gene-expression PLSR model. VIP scores were computed for the first three PLS components.

**Uniform manifold approximation and projection (UMAP)**—UMAP was performed in R using the umap package (0.2.7.0). For single-cell protein data, we first performed principal component analysis (PCA) using the prcomp() function on the z-scored log-transformed data and selected the PCA scores from the first four principal component for UMAP analysis. The parameters used in generating the UMAP for single-cell protein data include nearest neighbor (n\_neighbors) = 90, minimum distance (min\_dist) = 0.7 and distance metric (metric) = Euclidean.

**Hierarchical clustering**—Unsupervised hierarchical clustering of population-averaged AP-1 protein measurements was carried out in R using the stats (4.1.2) package. Clustering was performed using the hclust() function with the average algorithm as the agglomeration method. The distance matrix used for clustering was evaluated using the dist() function, with Pearson's correlation as the distance metric.

**Single-cell regulatory network inference and clustering (SCENIC)**—For the SCENIC analysis of melanoma cell lines, the baseline regulon activities inferred by the SCENIC workflow (Aibar et al., 2017; Van de Sande et al., 2020) were obtained from the .loom file published by Wouters et al. (Wouters et al., 2020). The .loom file was imported to R for downstream analysis using the SCoPeLoomR package (0.13.0).

Single-cell RNA sequencing data for patient-derived melanoma tumors were obtained from previous studies published by Tirosh et al. (Tirosh et al., 2016) and Jerby-Arnon et al. (Jerby-Arnon et al., 2018). Single-cell gene expression analysis and SCENIC was focused on 2072 malignant melanoma cells, which were distinguished (by the authors) from non-malignant cells based on gene copy number variations. For quality control, we first selected 14,689 genes which were detected in more than 1% of the cells (i.e., 20 cells) with at least 103 logged TPM counts, using the single-cell analysis toolkit Scanpy (1.7.1) (Wolf et al., 2018) in Python. Using this dataset, we then inferred regulons using pySCENIC (0.11.0) in a Nextflow pipeline adapted from Wouters et al. (Wouters et al., 2020), performing 100 SCENIC runs on the data. As in Wouters et al.'s regulon filtering criteria, only regulons that had more than 10 target genes and recurred in at least 80/100 runs were retained. Target genes (used in AUCCell calculation) that appear in at least 80% of the runs in regulons that recurred 100 times, and all target genes for regulons that recurred 80–100 times were retained. This analysis pipeline resulted in 373 motif regulons.

**Partial correlation analysis**—Partial correlation analysis is used for the evaluation of correlations between pairs of variables while controlling for the variance explained by a third variable. We used pairwise partial correlation analysis to evaluate correlations between changes induced by MAPK inhibitors in each of the AP-1 protein levels and p-ERK levels across different cell lines, while controlling for the baseline (drug-naïve) variance of AP-1 levels across the same cell lines. AP-1 and p-ERK data were averaged across two replicates and log-transformed. To assess if any of the AP-1 factors would capture drug-specific changes in ERK signaling, we then used the Matlab function `partialcorr()` to evaluate the Pearson's partial correlation coefficients (and the associated p values) between p-ERK and AP-1 levels across cell lines for each MAPK inhibitor treatment condition, while correcting for differences in their baseline (DMSO condition) AP-1 levels.

## QUANTIFICATION AND STATISTICAL ANALYSIS

Single-cell protein abundance was quantified from microscopy images using CellProfiler (3.1.9). No statistical method was used to predetermine sample size. Sample sizes were chosen based on similar studies in the relevant literature. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All boxplots and violin plots highlight the median, lower and upper quartiles. Whiskers in boxplots indicate 1.5 times interquartile ranges. Sample size (i.e., number of cells or replicates) are indicated in the figure legend. The significance of pairwise correlations were evaluated based on p values associated with the corresponding two-sided Pearson's correlation analysis. Statistical significance of changes in population-averaged protein abundance across different drugs and/or timepoints were determined based on one-way or two-way analysis of variance (ANOVA), as indicated in the figure legends. To identify the statistical significance of differences between mean of measurements of two different groups, p values were determined using paired or unpaired two-sided *t* test, as indicated in the figure legends. Statistical analyses were performed using MATLAB (2020b) and R (4.0.4).

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

We thank Kevin Janes and members of the Fallahi-Sichani laboratory for helpful suggestions and discussion. This work was supported by NIH grant R35-GM133404 (to M.F.-S.), the Farrow Fellowship (to D.G.B.), and grant P30-CA044579 (University of Virginia Cancer Center Support Grant). We acknowledge Research Computing at the University of Virginia for providing computational resources and technical support.

## REFERENCES

- Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, Rambow F, Marine J-C, Geurts P, Aerts J, et al. (2017). SCENIC: single-cell regulatory network inference and clustering. *Nat. Methods* 14, 1083–1086. 10.1038/nmeth.4463. [PubMed: 28991892]
- Arias AM, and Hayward P (2006). Filtering transcriptional noise during development: concepts and mechanisms. *Nat. Rev. Genet.* 7, 34–44. 10.1038/nrg1750. [PubMed: 16369570]

- Baron M, Tagore M, Hunter MV, Kim IS, Moncada R, Yan Y, Campbell NR, White RM, and Yanai I (2020). The stress-like cancer cell state is a consistent component of tumorigenesis. *Cell Syst.* 11, 536–546.e7. 10.1016/j.cels.2020.08.018. [PubMed: 32910905]
- Battich N, Stoeger T, and Pelkmans L (2015). Control of transcript variability in single mammalian cells. *Cell* 163, 1596–1610. 10.1016/j.cell.2015.11.018. [PubMed: 26687353]
- Becht E, McInnes L, Healy J, Dutertre C-A, Kwok IWH, Ng LG, Ginhoux F, and Newell EW (2018). Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* 37, 38–44. 10.1038/nbt.4314.
- Belote RL, Le D, Maynard A, Lang UE, Sinclair A, Lohman BK, Planells-Palop V, Baskin L, Tward AD, Darmanis S, and Judson-Torres RL (2021). Human melanocyte development and melanoma dedifferentiation at single-cell resolution. *Nat. Cell Biol.* 23, 1035–1047. 10.1038/s41556-021-00740-8. [PubMed: 34475532]
- Boumahdi S, and de Sauvage FJ (2020). The great escape: tumour cell plasticity in resistance to targeted therapy. *Nat. Rev. Drug Discov.* 19, 39–56. 10.1038/s41573-019-0044-1. [PubMed: 31601994]
- Davies AE, Pargett M, Siebert S, Gillies TE, Choi Y, Tobin SJ, Ram AR, Murthy V, Juliano C, Quon G, et al. (2020). Systems-level properties of EGFR-RAS-ERK signaling amplify local signals to generate dynamic gene expression heterogeneity. *Cell Syst.* 11, 161–175.e5. 10.1016/j.cels.2020.07.004. [PubMed: 32726596]
- Emert BL, Cote CJ, Torre EA, Dardani IP, Jiang CL, Jain N, Shaffer SM, and Raj A (2021). Variability within rare cell states enables multiple paths toward drug resistance. *Nat. Biotechnol.* 39, 865–876. 10.1038/s41587-021-00837-3. [PubMed: 33619394]
- Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, et al. (2019). HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy. *Cancer Res.* 79, 2947–2961. 10.1158/0008-5472.CAN-19-0040. [PubMed: 30987999]
- Fallahi-Sichani M, Moerke NJ, Niepel M, Zhang T, Gray NS, and Sorger PK (2015). Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. *Mol. Syst. Biol.* 11, 797. 10.15252/msb.20145877. [PubMed: 25814555]
- Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, Shah P, Rotem A, Garraway LA, and Sorger PK (2017). Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. *Mol. Syst. Biol.* 13, 905. 10.15252/MSB.20166796. [PubMed: 28069687]
- Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SK, Muhlich J, Chen J-Y, Vallabhaneni S, Baker GJ, Schapiro D, et al. (2020). Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells. *Cell Syst.* 11, 478–494.e9. 10.1016/j.cels.2020.10.002. [PubMed: 33113355]
- Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, et al. (2019). Nextgeneration characterization of the cancer cell line Encyclopedia. *Nature* 569, 503–508. 10.1038/s41586-019-1186-3. [PubMed: 31068700]
- Gillies TE, Pargett M, Minguet M, Davies AE, and Albeck JG (2017). Linear integration of ERK activity predominates over persistence detection in Fra-1 regulation. *Cell Syst.* 5, 549–563.e5. 10.1016/j.cels.2017.10.019. [PubMed: 29199017]
- Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, and Lander ES (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. *Cell* 146, 633–644. 10.1016/j.cell.2011.07.026. [PubMed: 21854987]
- Gut G, Herrmann MD, and Pelkmans L (2018). Multiplexed protein maps link subcellular organization to cellular states. *Science* 361, eaar7042. 10.1126/science.aar7042. [PubMed: 30072512]
- Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, et al. (2021). Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. *Nat. Cancer* 2, 693–708. 10.1038/s43018-021-00221-9. [PubMed: 35121945]

- Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigm. Cell Res.* 19, 290–302. 10.1111/j.600-0749.2006.00322.x.
- Huang S (2009). Non-genetic heterogeneity of cells in development: more than just noise. *Development* 136, 3853–3862. 10.1242/dev.035139. [PubMed: 19906852]
- Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su M-J, Melms JC, Leeson R, Kanodia A, Mei S, Lin J-R, et al. (2018). A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. *Cell* 175, 984–997.e24. 10.1016/j.cell.2018.09.006. [PubMed: 30388455]
- Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, and Garraway LA (2013). A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. *Nature* 504, 138–142. 10.1038/nature12688. [PubMed: 24185007]
- Karin M (1995). The regulation of AP-1 activity by mitogen-activated protein kinases. *J. Biol. Chem.* 270, 16483–16486. 10.1074/jbc.270.28.16483. [PubMed: 7622446]
- Khaliq M, Manikkam M, Martinez ED, and Fallahi-Sichani M (2021). Epigenetic modulation reveals differentiation state specificity of oncogene addiction. *Nat. Commun.* 12, 1536. 10.1038/s41467-021-21784-2. [PubMed: 33750776]
- Kong X, Kuilman T, Shahrazi A, Boshuizen J, Kemper K, Song J-Y, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, and Peeper DS (2017). Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. *Nature* 550, 270–274. 10.1038/nature24037. [PubMed: 28976960]
- Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, et al. (2014). A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. *Cancer Discov.* 4, 816–827. 10.1158/2159-8290.CD-13-0424. [PubMed: 24771846]
- Lin JY, and Fisher DE (2007). Melanocyte biology and skin pigmentation. *Nature* 445, 843–850. 10.1038/nature05660. [PubMed: 17314970]
- Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, et al. (2012). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. *Cancer Cell* 22, 668–682. 10.1016/j.ccr.2012.10.009. [PubMed: 23153539]
- Lopez-Bergami P, Lau E, and Ronai Z (2010). Emerging roles of ATF2 and the dynamic AP1 network in cancer. *Nat. Rev. Cancer* 10, 65–76. 10.1038/nrc2681. [PubMed: 20029425]
- Lundberg SM, and Lee S-I (2017). A unified approach to interpreting model predictions. In *Advances in Neural Information Processing Systems* (Curran Associates, Inc.).
- Lundberg SM, Nair B, Vavilala MS, Horibe M, Eisses MJ, Adams T, Liston DE, Low DK-W, Newman S-F, Kim J, and Lee SI (2018). Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. *Nat. Biomed. Eng.* 2, 749–760. 10.1038/s41551-018-0304-0. [PubMed: 31001455]
- Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal N, and Lee S-I (2020). From local explanations to global understanding with explainable AI for trees. *Nat. Mach. Intell.* 2, 56–67. 10.1038/s42256-019-0138-9. [PubMed: 32607472]
- Madrigal P, and Alasoo K (2018). AP-1 takes centre stage in enhancer chromatin dynamics. *Trends Cell Biol.* 28, 509–511. 10.1016/j.tcb.2018.04.009. [PubMed: 29778529]
- Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D, Swings T, et al. (2021). Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. *Cancer Cell* 39, 1135–1149.e8. 10.1016/j.ccell.2021.05.015. [PubMed: 34143978]
- Martínez-Zamudio RI, Roux P-F, de Freitas JANLF, Robinson L, Doré G, Sun B, Belenki D, Milanovic M, Herbig U, Schmitt CA, et al. (2020). AP-1 imprints a reversible transcriptional programme of senescent cells. *Nat. Cell Biol.* 22, 842–855. 10.1038/s41556-020-0529-5. [PubMed: 32514071]
- Maurus K, Hufnagel A, Geiger F, Graf S, Berking C, Heinemann A, Paschen A, Kneitz S, Stigloher C, Geissinger E, et al. (2017). The AP-1 transcription factor FOSL1 causes melanocyte

reprogramming and transformation. *Oncogene* 36, 5110–5121. 10.1038/onc.2017.135. [PubMed: 28481878]


- McQuin C, Goodman A, Chernyshev V, Kamensky L, Cimini BA, Karhohs KW, Doan M, Ding L, Rafelski SM, Thirstrup D, et al. (2018). Cell-Profiler 3.0: next-generation image processing for biology. *PLoS Biol.* 16, e2005970. 10.1371/journal.pbio.2005970. [PubMed: 29969450]
- Mica Y, Lee G, Chambers SM, Tomishima MJ, and Studer L (2013). Modeling neural crest induction, melanocyte specification, and disease-related pigmentation defects in hESCs and patient-specific iPSCs. *Cell Rep.* 3, 1140–1152. 10.1016/j.celrep.2013.03.025. [PubMed: 23583175]
- Mitchell S, and Hoffmann A (2018). Identifying Noise Sources governing cell-to-cell variability. *Curr. Opin. Struct. Biol.* 8, 39–45. 10.1016/j.coisb.2017.11.013.
- Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PDM, Geukes Foppen MH, et al. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. *Nat. Commun.* 5, 5712. 10.1038/ncomms6712. [PubMed: 25502142]
- Munsky B, Neuert G, and van Oudenaarden A (2012). Using gene expression noise to understand gene regulation. *Science* 336, 183–187. 10.1126/science.1216379. [PubMed: 22499939]
- Pedraza JM, and van Oudenaarden A (2005). Noise propagation in gene networks. *Science* 307, 1965–1969. 10.1126/science.1109090. [PubMed: 15790857]
- Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, Blondel M, Müller A, Nothman J, Louppe G, et al. (2018). Scikit-learn: machine learning in Python. Preprint at arXiv. 10.48550/arXiv.1201.0490.
- Phanstiel DH, Van Bortle K, Spacek D, Hess GT, Shamim MS, Machol I, Love MI, Aiden EL, Bassik MC, and Snyder MP (2017). Static and dynamic DNA loops form AP-1-bound activation hubs during macrophage development. *Mol. Cell* 67, 1037–1048.e6. 10.1016/j.molcel.2017.08.006. [PubMed: 28890333]
- Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, et al. (2018). Toward minimal residual disease-directed therapy in melanoma. *Cell* 174, 843–855.e19. 10.1016/j.cell.2018.06.025. [PubMed: 30017245]
- Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, et al. (2015). The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. *Sci. Signal.* 8, ra82. 10.1126/sci-signal.aab1111. [PubMed: 26286024]
- Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, et al. (2015). MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. *Nat. Commun.* 6, 8755. 10.1038/ncomms9755. [PubMed: 26530832]
- Rodríguez-Martínez JA, Reinke AW, Bhimsaria D, Keating AE, and Ansari AZ (2017). Combinatorial bZIP dimers display complex DNA-binding specificity landscapes. *Elife* 6, e19272. 10.7554/eLife.19272. [PubMed: 28186491]
- Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, et al. (2017). Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. *Nature* 546, 431–435. 10.1038/nature22794. [PubMed: 28607484]
- Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 141, 69–80. 10.1016/j.cell.2010.02.027. [PubMed: 20371346]
- Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, et al. (2016). Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. *Cancer Cell* 29, 270–284. 10.1016/j.ccell.2016.02.003. [PubMed: 26977879]
- Symmons O, and Raj A (2016). What's luck got to do with it: single cells, multiple fates, and biological nondeterminism. *Mol. Cell* 62, 788–802. 10.1016/j.molcel.2016.05.023. [PubMed: 27259209]

- Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* 352, 189–196. 10.1126/science.aad0501. [PubMed: 27124452]
- Torre EA, Arai E, Bayatpour S, Jiang CL, Beck LE, Emert BL, Shaffer SM, Mellis IA, Fane ME, Alicea GM, et al. (2021). Genetic screening for single-cell variability modulators driving therapy resistance. *Nat. Genet.* 53, 76–85. 10.1038/s41588-020-00749-z. [PubMed: 33398196]
- Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, et al. (2018). Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. *Cancer Cell* 33, 890–904.e5. 10.1016/j.ccell.2018.03.017. [PubMed: 29657129]
- Van de Sande B, Flerin C, Davie K, De Waegeneer M, Hulselmans G, Aibar S, Seurinck R, Saelens W, Cannoodt R, Rouchon Q, et al. (2020). A scalable SCENIC workflow for single-cell gene regulatory network analysis. *Nat. Protoc.* 15, 2247–2276. 10.1038/s41596-020-0336-2. [PubMed: 32561888]
- Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA, Roberts CWM, and Greenberg ME (2017). AP-1 transcription factors and the BAF complex mediate signal-dependent enhancer selection. *Mol. Cell* 68, 1067–1082.e12. 10.1016/j.molcel.2017.11.026. [PubMed: 29272704]
- Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, and Bonovich M (2002). Classification of human B-ZIP proteins based on dimerization properties. *Mol. Cell Biol.* 22, 6321–6335. 10.1128/MCB.22.18.6321-6335.2002. [PubMed: 12192032]
- Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, and Marais R (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. *PLoS One* 3, e2734. 10.1371/journal.pone.0002734. [PubMed: 18628967]
- Wold S (1994). Exponentially weighted moving principal components analysis and projections to latent structures. *Chemometr. Intell. Lab. Syst.* 23, 149–161.
- Wolf FA, Angerer P, and Theis FJ (2018). SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* 19, 15. 10.1186/s13059-017-1382-0. [PubMed: 29409532]
- Wouters J, Kalender-Atak Z, Minnoye L, Spanier KI, De Waegeneer M, Bravo González-Blas C, Mauduit D, Davie K, Hulselmans G, Najem A, et al. (2020). Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. *Nat. Cell Biol.* 22, 986–998. 10.1038/s41556-020-0547-3. [PubMed: 32753671]



**Highlights**

- AP-1 protein levels in a melanoma cell can predict its differentiation state
- Higher cFOS levels associate with differentiated and transitory cells
- FRA1, FRA2, and cJUN correlate with less differentiated states
- Perturbing AP-1 molecular balance induces cell-state switching



**Figure 1. Single-cell AP-1 protein levels predict differentiation state heterogeneity in melanoma cells**

(A) Schematic representation of the iterative indirect immunofluorescence imaging (4i) procedure used in this study to generate multiplexed single-cell data on 17 AP-1 proteins and 4 differentiation state markers. Representative images of selected AP-1 transcription factors and differentiation state markers are shown for LOXIMVI cells. Scale bars represent 20  $\mu$ m. Hoechst staining of nuclei is shown in blue, while staining of the indicated protein is shown in red.

(B) Population-averaged measurements of 17 AP-1 proteins and 4 differentiation state markers acquired across 19 BRAF-mutant melanoma cell lines. Protein data shown for each condition represent the log-transformed mean values for two replicates, followed by Z scoring across all cell lines. Data are organized only on the basis of hierarchical clustering of AP-1 protein measurements with Pearson correlation distance metric and the average algorithm for computing distances between clusters.

(C) Natural frequency of cells in each differentiation state (defined on the basis of MITF, SOX10, NGFR, and AXL levels) across 19 BRAF-mutant melanoma cell lines.

(D) The percentage of cells sampled from each of the 19 cell lines and their corresponding differentiation states used in the random forest model.


(E) Confusion matrix showing the independent validation performance of the random forest classifier in predicting the differentiation state of cells on the basis of single-cell AP-1 measurements. The model was trained using a group of 8,000 cells and validated using an independent group of 2,000 cells. The prediction accuracy and area under the receiver operating characteristic curve (ROC AUC) are shown as an overall measure of the classifier performance.

(F) Distributions of shapley additive explanations (SHAP) scores for each AP-1 factor across individual cells from the independent validation set. The color indicates the Z score-scaled, log-transformed level of each AP-1 protein at a single-cell level. For each differentiation state, AP-1 factors are ordered on the basis of the mean absolute values of their SHAP scores.

(G) Classification performance of the random forest model on the basis of varying numbers of top AP-1 factors (on the basis of their SHAP values) used as pre-dictors.

(H) UMAP analysis of the sampled melanoma cells (as shown in D) on the basis of their multiplexed levels of top 6 predictive AP-1 measurements (FRA2, p-cFOS, ATF4, cFOS, p-FRA1, and cJUN). Cells are colored on the basis of their differentiation states.

(I) Single-cell levels of the top six AP-1 proteins overlaid on UMAP plots for representative cell lines.



**Figure 2. AP-1 transcript levels predict variations in differentiation state across melanoma lines**

(A) Comparison between differentiation signature scores computed on the basis of RNA sequencing data for 53 cell lines reported by Tsoi et al. (left) and PLSR-predicted scores (following leave-one-out cross-validation) for each cell line on the basis of their transcript levels of 15 AP-1 genes (right). M, melanocytic; MT, melanocytic-transitory; T, transitory; TN, transitory-neural crest-like; N, neural crest-like; NU, neural crest-like-undifferentiated; U, undifferentiated.

(B) Performance of the PLSR model evaluated by computing the fraction of variance in differentiation signature scores explained ( $R^2$ ) or predicted on the basis of leave-one-out cross validation ( $Q^2$ ) with increasing number of PLS components.

(C) Comparison between differentiation signature scores computed on the basis of RNA sequencing data of 32 CCLE cell lines (left) and predicted scores on the basis of the PLSR model built for the original set of 53 cell lines (right).

(D) PLSR scores (of the first two PLS components) for each cell line colored according to their differentiation signature scores for melanocytic, transitory, neural crest-like, and undifferentiated states.

(E) PLSR-derived variable importance in projection (VIP) scores, highlighting combinations of AP-1 transcripts that are predictive of differentiation signature scores for melanocytic, transitory, neural crest-like, and undifferentiated states. The sign of the VIP score shows whether the indicated variable (AP-1 transcript level) positively or negatively contributes to a given differentiation signature. Significant VIP scores (of greater than 1 or smaller than -1) are highlighted.


(F) Comparison of performance (with respect to differentiation state prediction) between the PLSR model based on transcript levels of the top 8 AP-1 transcription factors with models based on transcript levels of combinations of 8 randomly chosen bZIP family transcription factors ( $n = 1 \times 10^5$  iterations; left panel) or built on the basis of 8 randomly chosen transcription factors ( $n = 5 \times 10^5$  iterations; right panel). Empirical p values were reported for the comparison of predicted variances on the basis of ten-fold cross-validation.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 3. Single-cell network inference reveals the role of AP-1 activity in regulation of differentiation state programs**

(A–D) Single-cell distributions of the activity of SCENIC regulons for FOSL2 (A), JUN (B), FOSL1 (C), and FOS (D) motifs, measured using AUCCell in individual cells (from 10 melanoma cell lines profiled by Wouters et al.) across distinct differentiation states. The differentiation state of individual cells was determined on the basis of their gated levels of enrichment (quantified by AUCCell) for the differentiation gene signatures as defined by Tsoi et al.


(E–I) Single-cell distributions of the AUCCell activity of SCENIC regulons for FOSL2 (E), JUN (F), FOSL1 (G), and FOS (H) motifs, as well as the ratio of FOS and JUN regulon activities (I), quantified in individual cells from 11 treatment-naive melanoma tumors as profiled by Tirosh et al. and Jerby-Arnon et al. Statistical comparisons were performed using two-sided unpaired t tests. Boxplot hinges correspond to the lower and upper quartiles, with a band at the median. Whiskers indicate 1.5 times interquartile ranges.



**Figure 4. MAPK inhibitor-induced changes in AP-1 protein levels, p-ERK and differentiation state markers**

(A) Population-averaged measurements of 17 AP-1 proteins, differentiation state markers MITF and NGFR, and p-ERK<sup>T202/Y204</sup> levels acquired across 18 BRAF-mutant melanoma cell lines. Protein data shown for each condition represent the log-transformed mean values for two replicates, followed by Z scoring across all cell lines and treatment conditions, including DMSO, vemurafenib alone (at 0.316  $\mu$ M), or the combination of vemurafenib (at 0.316  $\mu$ M) and trametinib (at 0.0316 mM) for 24 or 72 h.

(B) MAPK inhibitor-induced changes in differentiation state, as evaluated by log-transformed ratio of NGFR to MITF protein levels across cell lines at 72 h. Central marks on the data points indicate the mean between two replicates. p values represent one-way ANOVA test for differences across treatment conditions in each cell line.



**Figure 5. MAPK inhibitor-induced changes in cJUN and p-cJUN levels correlate with drug-induced changes in differentiation states**


(A) Performance of the PLSR model in predicting drug-induced changes in differentiation states on the basis of drug-induced AP-1 modifications. Model performance was evaluated by computing the fraction of variance in DMSO-normalized differentiation state changes at 72 h explained ( $R^2$ ) or predicted on the basis of leave-one-out cross validation ( $Q^2$ ) with increasing number of PLS components.

(B) PLSR-derived variable importance in projection (VIP) scores, highlighting combinations of DMSO-normalized AP-1 modifications at 24 and 72 h, and their importance for predicting the DMSO-normalized differentiation state changes at 72 h. The sign of the VIP score shows whether the indicated variable (DMSO-normalized AP-1 protein levels at 24 or 72 h) positively or negatively contributes to the response (DMSO-normalized change in differentiation state).

(C) Pearson's correlation between DMSO-normalized changes in differentiation state and DMSO-normalized cJUN or p-cJUN levels at indicated time points and drug treatment conditions. Each data point represents population-averaged measurements across two replicates for each cell line.

(D) Analysis of covariance between the levels of p-cJUN or c-JUN and drug-induced changes in differentiation state (as evaluated by NGFR-MITF ratio) at the single-cell level across indicated treatment conditions. For each cell line, Pearson's correlation coefficient was calculated on the basis of 300 randomly sampled cells (100 cells from each treatment condition).





**Figure 6. MAPK inhibitor-induced changes in p-FRA1 levels correlate with efficiency of ERK pathway inhibition across cell lines**


(A) Population-averaged measurements of p-ERK<sup>T202/Y204</sup> levels in 18 cell lines following indicated MAPK inhibitor treatments for 24 or 72 h. Bar height indicates mean values between two replicates shown as black dots. p values show the statistical significance of the impact of MAPK inhibitor treatment (blue) or time (red) on p-ERK levels on the basis of two-way ANOVA.

(B) Statistical comparison (using two-sided paired t test) of p-ERK levels across 18 cell lines following indicated MAPK inhibitor treatments for 24 or 72 h. Each data point represents population mean of p-ERK levels between two replicates for each cell line.

(C) Pairwise partial correlations (evaluated across 18 cell lines) between each of the 17 AP-1 measurements and p-ERK levels following 24 or 72 h of treatment with MAPK inhibitors, while correcting for the corresponding baseline (drug-naïve) AP-1 levels in the same cell lines.

(D) Pearson's correlation (top row) and partial correlation (bottom row) between p-ERK and p-FRA1 levels following MAPK inhibitor treatments at indicated time points. Each data point represents population mean of p-ERK levels between two replicates for each cell line.

(E) Analysis of covariance between p-FRA1 and p-ERK levels across indicated MAPK inhibitor treatment conditions at the single-cell level. For each cell line, Pearson's correlation coefficient was calculated on the basis of 400 randomly sampled cells (100 cells from each treatment condition).



**Figure 7. Perturbation of AP-1 state by siRNA confirms its role in driving differentiation state heterogeneity**

(A) The effect of siRNA-mediated depletion (for 96 h) of AP-1 proteins cFOS, FRA2, cJUN, and JUND, either individually or in pairwise combinations, on protein levels of cFOS, FRA1, FRA2, cJUN, and JUND and differentiation state markers MITF and SOX10 in COLO858 cells. Protein data shown for each condition represent the log-transformed mean values for three and six replicates across AP-1 knockdown conditions and the control, respectively. The central mark on the plots indicates the median across replicates. Statistical comparisons were performed using two-sided unpaired t tests.

(B) Two-dimensional projection of MITF and SOX10 levels (in log scale) following 96 h of siRNA knockdown in COLO858 cells.

(C and D) Statistical comparison (using two-sided unpaired t test) of selected AP-1 proteins and SOX10 levels across indicated siRNA knockdown conditions in C32 (C) and LOXIMVI (D) cells. Protein data shown for each condition represent the log-transformed mean values for three and six replicates across AP-1 knock-down conditions and the control, respectively. The central mark on the plots indicates the median across replicates.

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
c-Fos (9F6) Rabbit mAb	Cell Signaling Technologies	Cat# 2250, RRID: AB_2247211
Phospho-c-Fos (Ser32) (D82C12) XP® Rabbit mAb	Cell Signaling Technologies	Cat# 5348, RRID: AB_10557109
Recombinant Anti-FRA1 [EP4711] Rabbit mAb	Abcam	Cat# ab124722, RRID: AB_11001005
Phospho-FRA1 (Ser265) (D22B1) Rabbit mAb	Cell Signaling Technologies	Cat# 5841, RRID: AB_10835210
Fra2 (D2F1E) Rabbit mAb	Cell Signaling Technologies	Cat# 19967, RRID: AB_2722526
c-Jun (60A8) Rabbit mAb	Cell Signaling Technologies	Cat# 9165, RRID: AB_2130165
Phospho-c-Jun (Ser73) (D47G9) XP® Rabbit mAb	Cell Signaling Technologies	Cat# 3270, RRID: AB_2129575
JunD (D17G2) Rabbit mAb	Cell Signaling Technologies	Cat# 5000, RRID: AB_10949318
JunB (C37F9) Rabbit mAb	Cell Signaling Technologies	Cat# 3753, RRID: AB_2130002
Phospho Anti-ATF1 (S63) Rabbit mAb	Abcam	Cat# ab76085, RRID: AB_1523174
Recombinant Anti-ATF2 [E243]	Abcam	Cat# ab32160, RRID: AB_2243137
Recombinant Anti-ATF2 (phospho T71) [E268]	Abcam	Cat# ab32019, RRID: AB_725567
Anti-ATF3	Abcam	Cat# ab87213, RRID: AB_1951498
Recombinant Anti-ATF4 antibody [EPR18111]	Abcam	Cat# ab184909, RRID: AB_2819059
Anti-ATF4 (phospho S245)	Abcam	Cat# ab28830, RRID: AB_725570
Recombinant Anti-ATF5 [EPR18286]	Abcam	Cat# ab184923, RRID: AB_2800462
Anti-ATF6 antibody [1-7]	Abcam	Cat# ab122897, RRID: AB_10899171
Phospho pErk1/2 (T202/Y204) Rabbit mAb	Cell Signaling Technologies	Cat# 4370, RRID: AB_2315112
Human MITF Antibody	R&D Systems	Cat# AF5769, RRID: AB_2235141
Anti-SOX10 antibody [SOX10/991]	Abcam	Cat# ab212843, RRID: AB_2889150
p75NTR Rabbit mAb	Cell Signaling Technologies	Cat# 8238, RRID: AB_10839265
Human Axl Antibody	R&D Systems	Cat# AF154, RRID: AB_354852
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647	Invitrogen	Cat# A-21245, RRID: AB_141775
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 568	Invitrogen	Cat# A-11004, RRID: AB_2534072
Chemicals, peptides, and recombinant proteins		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Venurafenib	Selleck Chemicals	Cat# S1267
Trametinib	Selleck Chemicals	Cat# S2673
DharmaFECT 2	Horizon Discovery	Cat# T-2002-01
MycroAlert™ PLUS Mycoplasma Detection Kit	Lonza	Cat# LT07-701
DMEM with 4.5 g/L glucose	Corning	Cat# 10-013-CV
Fetal bovine serum	Gibco	Cat# 26140079
EMEM	Corning	Cat# 10-009-CV
DMEM/F12	Gibco	Cat# 11330-032
Sodium pyruvate	Gibco	Cat# 11360070
RPMI 1640	Corning	Cat# 10-040-CV
Plasmocin Prophylactic	Invivogen	Cat# NC9886956
L-Glycine	Sigma	Cat# 50046
Urea	Sigma	Cat# U5128
Guanidinium chloride	Sigma	Cat# 3272
TCEP-HCl	Sigma	Cat# C4706
Intercept blocking buffer	LiCor	Cat# 927-70001
Maleimide	Sigma	Cat# 129585
N-Acetyl-Cysteine	Sigma	Cat# A7250
Hoechst 33342	Invitrogen	Cat# H3570
CellMask Green	ThermoFisher	Cat# C37608
Deposited data		
Single cell 4i protein measurements (Data S1, S4, and S5)	This paper	N/A
Bulk gene expression data for 53 melanoma cell lines	(Tsoi et al., 2018)	GEO Accession: GSE80829
Bulk gene expression data for 32 melanoma cell lines from the Cancer Cell Line Encyclopedia (CCLE).	(Ghandi et al., 2019)	<a href="https://sites.broadinstitute.org/ccle">https://sites.broadinstitute.org/ccle</a>
SCENIC regulons of 10 melanoma cell lines	(Wouters et al., 2020)	<a href="http://scope.aertslab.org/#/Wouters_Human_Melanoma">http://scope.aertslab.org/#/Wouters_Human_Melanoma</a>
Single cell gene expression data of patient-derived melanoma tumors	(Jerby-Arnon et al., 2018; Tirosch et al., 2016)	GEO Accession: GSE72056; GSE115978
Single cell signature enrichment and regulon activity data of melanoma cell lines and patient-derived tumors (Data S2 and S3)	This paper	N/A
AP-1 siRNA knockdown effects in melanoma cell lines measured by 4i (Data S6)	This paper	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental models: Cell lines		
Human: COLO858, Melanoma Cell Line	MGH Cancer Center, primary source ECACC	Cat# 93052613, RRID: CVCL_2005
Human: RVH421, Melanoma Cell Line	MGH Cancer Center, primary source DSMZ	Cat# ACC 127, RRID: CVCL_1672
Human: A375, Melanoma Cell Line	ATCC	Cat# CRL-1619, RRID: CVCL_0132
Human: A375 NRAS(Q61K), Melanoma Cell Line	ATCC	Cat# CRL-1619IG-2, RRID: CVCL_JF22
Human: C32, Melanoma Cell Line	MGH Cancer Center, primary source ATCC	Cat# CRL-1585, RRID: CVCL_5246
Human: A2058, Melanoma Cell Line	ATCC	Cat# CRL-11147, RRID: CVCL_1059
Human: WM115, Melanoma Cell Line	MGH Cancer Center, primary source ATCC	Cat# CRL-1619, RRID: CVCL_0040
Human: SKMEL28, Melanoma Cell Line	MGH Cancer Center, primary source ATCC	Cat# HTB-72, RRID: CVCL_0526
Human: HS294T, Melanoma Cell Line	ATCC	Cat# HTB-140, RRID: CVCL_0331
Human: WM1552C, Melanoma Cell Line	MGH Cancer Center, primary source ATCC	Cat# CRL-2808, RRID: CVCL_6472
Human: SKMEL5, Melanoma Cell Line	ATCC	Cat# HTB-70, RRID: CVCL_0527
Human: A101D, Melanoma Cell Line	ATCC	Cat# CRL-7898, RRID: CVCL_1057
Human: IGR39, Melanoma Cell Line	DSMZ	Cat# ACC 239, RRID: CVCL_2076
Human: LOXIMVI, Melanoma Cell Line	MGH Cancer Center, primary source Sigma	Cat# SCC201, RRID: CVCL_1381
Human: MMACSF, Melanoma Cell Line	MGH Cancer Center, primary source RIKEN BioResource Center	Cat# RCB1200, RRID: CVCL_1420
Human: WM902B, Melanoma Cell Line	Wistar	Cat# WM902B-01-0001, RRID: CVCL_6807
Human: WM2664, Melanoma Cell Line	Wistar	Cat# WM266-4-01-0001, RRID: CVCL_2765
Human: UACC62, Melanoma Cell Line	Broad Institute, primary source N/A	RRID: CVCL_1780
Human: SKMEL19, Melanoma Cell Line	Broad Institute, primary source N/A	RRID: CVCL_6025

## Oligonucleotides

See Table S1 for oligonucleotide sequences.

This paper

N/A

## Software and algorithms

Source code for analyses

<https://github.com/fallah-sichani-lab/API-networkPlasticityMelanoma>

CellProfiler (3.1.9)

<https://cellprofiler.org/>

ImageJ (2.3.0)

<https://imagej.nih.gov/ij/index.html>

MATLAB (2020b)

<https://matlab.mathworks.com/>

REAGENT or RESOURCE	SOURCE	IDENTIFIER
R (4.0.4)	The Comprehensive R Archive Network (CRAN)	<a href="https://www.r-project.org/">https://www.r-project.org/</a>
stats R package (4.1.2)	The R Project	<a href="https://stat.ethz.ch/R-manual/R-devel/library/stats/html/00Index.html">https://stat.ethz.ch/R-manual/R-devel/library/stats/html/00Index.html</a>
AUCell R package (1.16.0)	(Albareta, 2017)	<a href="https://bioconductor.org/packages/release/bioc/vignettes/AUCell/inst/doc/AUCell.html">https://bioconductor.org/packages/release/bioc/vignettes/AUCell/inst/doc/AUCell.html</a>
umap R package (0.2.7.0)	CRAN	<a href="https://cran.r-project.org/web/packages/umap/">https://cran.r-project.org/web/packages/umap/</a>
SCopeLoomR R package (0.13.0)	Aerts Lab	<a href="https://github.com/aertslab/SCopeLoomR">https://github.com/aertslab/SCopeLoomR</a>
Python (3.9.2)	N/A	<a href="https://www.python.org/downloads/">https://www.python.org/downloads/</a>
Scanny (1.7.1)	(Wolf et al., 2018)	<a href="https://github.com/scverse/scanny">https://github.com/scverse/scanny</a>
pySCENIC (0.11.0)	(Van de Sande et al., 2020)	<a href="https://github.com/aertslab/SCENICprotocol">https://github.com/aertslab/SCENICprotocol</a>
Nextflow (20.10.0)	Seqera Labs	<a href="https://www.nextflow.io/">https://www.nextflow.io/</a>
Scikit-learn Library (0.24.1)	(Pedregosa et al., 2018)	<a href="https://scikit-learn.org/stable/">https://scikit-learn.org/stable/</a>
SHAP	(Lundberg and Lee, 2017)	<a href="https://github.com/slundberg/shap">https://github.com/slundberg/shap</a>
Other		
96-well plates	Corning	Cat# 3904
Differentiation signature gene sets	(Tsoi et al., 2018)	N/A
Proliferative and Invasive phenotype gene sets	(Hoek et al., 2006)	<a href="http://www.jurmo.ch/work_97.php">http://www.jurmo.ch/work_97.php</a>
List of bZIP transcription factor genes	(Vinson et al., 2002)	<a href="https://github.com/fallah-sichani-lab/API-networkPlasticityMelanoma">https://github.com/fallah-sichani-lab/API-networkPlasticityMelanoma</a>
List of transcription factor genes	(Van de Sande et al., 2020)	<a href="https://raw.githubusercontent.com/aertslab/pySCENIC/master/resources/hs_hgnc_tfs.txt">https://raw.githubusercontent.com/aertslab/pySCENIC/master/resources/hs_hgnc_tfs.txt</a>
Nextflow pipeline adapted for running SCENIC iteratively	(Wouters et al., 2020)	<a href="https://github.com/aertslab/singlecellRNA_melanoma_paper">https://github.com/aertslab/singlecellRNA_melanoma_paper</a>
R scripts adapted for extracting and filtering regulons from multiple SCENIC runs	(Wouters et al., 2020)	<a href="https://github.com/aertslab/singlecellRNA_melanoma_paper">https://github.com/aertslab/singlecellRNA_melanoma_paper</a>
Homo sapiens whole-genome motif ranking databases for SCENIC (motif collection v9)	Aerts Lab	<a href="https://resources.aertslab.org/cistarget/">https://resources.aertslab.org/cistarget/</a>
Motif annotation file for SCENIC (motif collection v9)	Aerts Lab	<a href="https://resources.aertslab.org/cistarget/">https://resources.aertslab.org/cistarget/</a>